Connection

Azizul Haque to Disease Models, Animal

This is a "connection" page, showing publications Azizul Haque has written about Disease Models, Animal.
Connection Strength

0.494
  1. Premarin Reduces Neurodegeneration and Promotes Improvement of Function in an Animal Model of Spinal Cord Injury. Int J Mol Sci. 2022 Feb 21; 23(4).
    View in: PubMed
    Score: 0.119
  2. Calpain activation and progression of inflammatory cycles in Parkinson's disease. Front Biosci (Landmark Ed). 2022 01 13; 27(1):20.
    View in: PubMed
    Score: 0.118
  3. Calpain mediated expansion of CD4+ cytotoxic T cells in rodent models of Parkinson's disease. Exp Neurol. 2020 08; 330:113315.
    View in: PubMed
    Score: 0.105
  4. Targeting Enolase in Reducing Secondary Damage in Acute Spinal Cord Injury in Rats. Neurochem Res. 2017 Oct; 42(10):2777-2787.
    View in: PubMed
    Score: 0.085
  5. Nanoparticle-Based Estrogen Delivery to Spinal Cord Injury Site Reduces Local Parenchymal Destruction and Improves Functional Recovery. J Neurotrauma. 2021 02; 38(3):342-352.
    View in: PubMed
    Score: 0.027
  6. Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and ROR?t responses and by increasing IL-10 production in experimental allergic encephalomyelitis. J Neuroimmunol. 2013 Jan 15; 254(1-2):117-24.
    View in: PubMed
    Score: 0.016
  7. Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010 Feb 26; 219(1-2):47-53.
    View in: PubMed
    Score: 0.013
  8. Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis. J Neuroimmunol. 2008 Nov 15; 204(1-2):58-65.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.